

LITERATURA

- Dušek L. Kulatý stůl Zdravotnického deníku. Praha, květen 2026.
- Registr CRediT. [Internet]. [cited 2026 Jun 11]. Available from: <https://credit.registry.cz/index.php>
- Hracs L, Windsor JW, Gorospe J, et al. Global evolution of inflammatory bowel disease across epidemiologic stages. *Nature*. 2025;642(8067):458-466.
- Meima-van Praag EM, Buskens CJ, Hompes R, et al. Surgical Management of Crohn's Disease: A State of the Art Review. *Int J Colorectal Dis*. 2021;36:1133-1145.
- Bortlík M. Doporučení pro diagnostiku a léčbu Crohnovy choroby. Přednáška. 17. vzdělávací a diskusní gastroenterologické dny, Karlovy Vary, 2022 Dec 2.
- Gordon H, Minozzi S, Kopylov U, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. *J Crohns Colitis*. 2024;18(10):1531-1555.
- Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology*. 2021;160(7):2496-2508.
- Donin G, Tichopád A. Analýza cesty pacienta s IBD na základě administrativních dat. Nepublikovaná výzkumná zpráva. Kladno: Fakulta biomedicínského inženýrství, ČVUT v Praze; 2025.
- Balducci D, Mosca M, Monaco S, et al. The Evolving Landscape of Advanced Therapies in Inflammatory Bowel Disease: Current Evidence and Emerging Targets. *Gastrointest Disord*. 2026;8(1):13.
- Tursi A, Mocchi G, Lorenzetti R, et al. Long-Term Real-Life Efficacy and Safety of Infliximab and Adalimumab in the Treatment of Inflammatory Bowel Diseases Outpatients. *Eur J Gastroenterol Hepatol*. 2021;33:670-679.
- Solitano V, Jairath V, Magro F, et al. Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality? *Lancet Gastroenterol Hepatol*. 2026;S2468-1253(26)00085-3.
- Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. *Gut*. 2019;68(3):423-433.
- Burisch J, Katsanos KH, Christodoulou DK, et al. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. *J Crohns Colitis*. 2019;13(2):198-208.
- Gómez-Labrador C, Ricart E, Iborra M, et al. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA. *Pharmaceutics*. 2024;16(5):629.
- Arora M, Khurana S, Lu I, et al. Review of Current Medical and Surgical Therapy for Inflammatory Bowel Disease. *J Clin Gastroenterol*. 2026 May 19. doi: 10.1097/MCG.0000000000002387. Online ahead of print.
- Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. *Lancet Gastroenterol Hepatol*. 2024;9(5):415-427.
- Noor NM, Davies N, Tahir W, et al. Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional „step-up“ care for patients with active Crohn's disease: a cost-effectiveness analysis from the PROFILE trial. *J Crohns Colitis*. 2025;19(9):jjaf150.

Pro věrné čtenáře

Součástí Vnitřního lékařství 4/2026 je navíc supplementum

Praktická doporučení – Expertní konsenzus pro diagnostiku a léčbu pacientů s hyperurikémií a vysokým kardiovaskulárním rizikem: aktualizace 2025




**5. kongres
diabetologie
pro praxi**

28. 1. 2027
CENTRAL PARK FLORA
OLOMOUC



Připravované tematické bloky:

- Novinky ve farmakoterapii
- Diabetes ve vyšším věku: geriatric, frailty, sarkopenie a kognice
- Cased based learning – interaktivní kazuistiky z diabetologie
- Diabetes a onkologie: obousměrný vztah a praktický management

MÍSTO KONÁNÍ:
CENTRAL PARK FLORA OLOMOUC
KRAPKOVA 439/34, OLOMOUC

